EGFR and non-small cell lung carcinoma: EGFR-TKIs have been established as standard first-line treatment for patients with EGFR-mutated advanced NSCLC, a conclusion primarily drawn from the trial’s demonstration of superior progression-free and overall survival benefits compared to chemotherapy [15, 52–54].